Hepatic surgery for metastases from neuroendocrine tumors

Surgical Oncology Clinics of North America

Volumn 12, Issue 1, 2003, Pages 231-242

  Sarmiento, Juan M ^a   Que, Florencia G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; STREPTOZOCIN;

ARTERY LIGATION; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CLINICAL FEATURE; CRYOTHERAPY; HUMAN; LIVER CIRCULATION; LIVER METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; REVIEW; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037276802     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(02)00076-5     Document Type: Review

References (55)

1. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108:1091-6.
2. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169:36-42.
3. Wong WJ, DeCosse JJ. Cytoreductive surgery. Surg Gynecol Obstet 1990;170:276-81.
4. Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1503-22.
5. Thompson GB, van Heerden JA, Grant CS, et al. Islet cell carcinoma of the pancreas: a twenty-year experience. Surgery 1988;104:1011-7.
6. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg 1992;215:8-18.
7. Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001;129:170-5.
8. Ahlman H, Westberg G, Wangberg B, et al. Treatment of liver metastases of carcinoid tumors. World J Surg 1996;20:196-202.
9. Sarmiento JM, Ilstrup DM, Nagorney DM, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Hepatology 2001;34:236A.
10. Ringe B, Lorf T, Kopkens K, Canelo R. Treatment of hepatic metastases from gastropancreatic neuroendocrine tumors: role of liver transplantation. World J Surg 2001;25:697-9.
11. Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. Ann Surg 1997;225:355-64.
12. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma. Transplantation 1998;66:1307-12.
13. Cozzi PJ, England R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995;76:501-9.
14. Bilchik AJ, Sarantou T, Foshag LJ, et al. Cryosurgical palliation of metastastic neuroendocrine tumors resistant to conventional therapy. Surgery 1997;122:1040-7.
15. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radio-frequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001;25:693-6.
16. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 1992;326:519-23.
17. Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. In: Foster JH, Berman MM, editors. Solid liver tumors. Vol 22. Philadelphia: WB Saunders; 1977. p. 235-245. Curr Opin Oncol 1998;10:58-65.
18. Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. In: Foster JH, Berman MM, editors. Solid liver tumors. Vol 22. Philadelphia: WB Saunders; 1977. p. 235-245. Curr Opin Oncol 1998;10:58-65.
19. Kvols LK. Therapy of malignant carcinoid syndrome. Endocrinol Metab Clin North Am 1989;18:557-68.
20. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
21. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999;10:S31-8.
22. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
23. Tiensuu Janson E, Ahlstrom H, Andersson T, Oberg K. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumor. Eur J Cancer 1992;28A:1647-50.
24. Tiensuu Janson E, Oberg K. Long-term management of the carcinoid syndrome. Acta Oncol 1993;32:225-9.
25. Wallace S, Ajani JA, Charnsangavej C, et al. Carcinoid tumors: imaging procedures and interventional radiology. World J Surg 1996;20:147-56.
26. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994;116:1111-6.
27. Melendez JA, Arslan V, Fischer ME. et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg 1998;187:620-5.
28. McDonald ML, Nagorney DM, Connolly HM, et al. Carcinoid heart disease and carcinoid syndrome: successful surgical treatment. Ann Thorac Surg 1999;67:537-9.
29. Proye C. Natural history of liver metastases of gastropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg 2001;25:685-8.
30. Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 2001;87:447-52.
31. Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991;30:547-53.
32. Aronsen KF, Torp A, Waldenstrom JG. A case of carcinoid syndrome followed for eight years after palliative liver resection. Acta Medica Scand 1976;199:327-9.
33. Battersby C, Egerton WS. A carcinoid saga. Aust N Z J Surg 1974;45:209-13.
34. Berney T, Mentha G, Roth AD, Morel P. Results of surgical resection of liver metastasis from non-colorectal primaries. Br J Anaesth 1998;85:1423-7.
35. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432-45.
36. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187:88-92.
37. Davis Z, Moertel CG, McIlrath D. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973;137:637-44.
38. Dousset B, Saint-Marc O, Pitre J, et al. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996;20:908-14.
39. Fortner JG, Kinne DW, Kim DK, et al. Vascular problems in upper abdominal cancer surgery. Arch Surg 1974;109:148-53.
40. Foster JH, Berman MM. Palliative liver resection to relieve symptoms of malignant carcinoid and other endocrine syndromes. In: Solid liver tumors. Vol. 22. Philadelphia: WB Saunders; 1977. p. 235-5.
41. Gillett DJ, Smith RC. Treatment of the carcinoid syndrome by hemihepatectomy and radical excision of primary lesion. Am J Surg 1974;128:95-9.
42. Grazi GL, Cescon M, Pierangeli F, et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 2000;47:481-6.
43. Jaeck D, Oussoultzoglou E, Bachellier P, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg 2001;25:689-92.
44. Kune GA, Goldstein J. Malignant liver carcinoid: the place of surgery and chemotherapy. Review and case presentation. Med J Aust 1974;2:777-80.
45. Lannon J. Seventeen cases of hepatectomy. S Afr J Surg 1974;12:227-32.
46. Longmire WPJ, Trout HHR, Greenfield J, Tompkins RK. Elective hepatic surgery. Ann Surg 1974;179:712-21.
47. Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990;14:377-83.
48. Norton JA, Sugarbaker PH, Doppman JL, et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986;203:352-9.
49. Reiss R, Antal SC. Indications for partial hepatectomy in metastatic disease. Bull Soc Int Chir 1974;33:172-7.
50. Soreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992;111:48-54.
51. Stehlin JSJ, De Ipoly PD, Greeff PJ, et al. Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients. Ann Surg 1988;208:23-35.
52. Stephen JL, Grahame-Smith DG. Treatment of the carcinoid syndrome by local removal of hepatic metastases. Proc R Soc Med 1972;65:444-5.
53. Taylor B, Langer B, Falk RE, Ambus U. Role of resection in the management of metastases to the liver. Can J Surg 1983;26:215-7.
54. Thompson HH, Tompkins RK, Longmire WPJ. Major hepatic resection: a 25-year experience. Ann Surg 1983;197:375-87.
55. Wolf RF, Goodnight JE, Krag DE, Schneider PD. Results of resection and proposed guidelines for patient selection in instances of noncolorectal hepatic metastases. Surg Gynecol Obstet 1991;173:454-60.